Get the app
US › Healthcare

Mereo BioPharma Group PLC ADR (MREO)

US · Healthcare · Biotechnology

$0.30-1.94%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-7.0M
EPS
$-0.01
EPS estimate
$-0.01

EPS came in at -0.01 against a street estimate of -0.01 — a beat of 0.0%.

Key statistics

Market cap
$51.1M
Forward P/E
0.0
P/B
1.91
Book value
$0.18
EPS (TTM)
$-0.20
52-week high
$2.37
52-week low
$0.20
50-day MA
$0.31
200-day MA
$0.36
Beta
0.14

Analyst view

Analysts rate Mereo BioPharma Group PLC ADR a buy (5 buy, 2 hold, 1 sell out of 8) with an average price target of $1.97.

Shareholding

Insiders
0.75%
Institutions
35.47%

Largest institutional holders

FundStake
Rubric Capital Management LP9.59%
683 Capital Management LLC7.51%
Bank of America Corp5.13%
Defilade Capital Management, L.P.4.73%
Newtyn Management LLC1.88%
Tejara Capital Ltd1.28%
UBS Group AG0.91%
Two Sigma Investments LLC0.83%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Mereo BioPharma Group PLC ADR — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-18.